Pheon Therapeutics is an Antibody-Drug Conjugate (ADC) specialist that creates ADCs for a variety of difficult-to-treat cancers. Its lead program is a first-in-class ADC against a novel target that is highly expressed in solid tumors across a broad range of hard-to-treat cancer types. The company was founded in 2022 and is based in London, England.
S2 Genomics, Inc. is a company based in Livermore, California, that specializes in developing advanced spatial sequencing technology. Founded in 2016, the company focuses on creating integrated sample preparation systems that automate the processing of solid tissues and liquid samples into genomic samples. This technology allows researchers to isolate single cells or nuclei from raw tissues, facilitating genomics and cell biology studies. S2 Genomics aims to streamline the preparation process, ensuring reproducibility and minimal impact on cellular transcriptomes, thereby optimizing the quantity and quality of viable cells or nuclei derived from various tissue types.
iotaMotion, Inc. is a company based in Iowa City, Iowa, that specializes in the development and manufacture of cochlear ear implants aimed at treating hearing loss. Founded in 2015, the company has created a robotic-assisted surgical system designed to standardize the insertion of cochlear implant electrodes. This innovative technology enhances surgical precision by controlling the speed and acceleration of electrode insertion, which helps to reduce variability in surgical procedures. By personalizing the approach to each patient, iotaMotion enables surgeons to provide more accurate and tailored cochlear interventions, ultimately expanding access to these critical treatments for both patients and healthcare providers.
Pheon Therapeutics is an Antibody-Drug Conjugate (ADC) specialist that creates ADCs for a variety of difficult-to-treat cancers. Its lead program is a first-in-class ADC against a novel target that is highly expressed in solid tumors across a broad range of hard-to-treat cancer types. The company was founded in 2022 and is based in London, England.
Halo Labs is a life science instrumentation company based in Burlingame, California, that specializes in developing tools for biologics researchers. Formerly known as Optofluidics, the company focuses on high throughput biopharmaceutical quality control, utilizing advanced optics, image processing, and microfluidics technology. Its offerings include tools for biologics-developability assessment, formulation development, small molecule solubility, and AAV analytics. Founded in 2011, Halo Labs has gained recognition in the industry, receiving support from notable investors and partners such as BioAdvance and the National Science Foundation. The company aims to provide researchers with accurate insights into the stability and quality of biological drugs.
SeqWell’s is a biotechnology company that specializes in the fields of gene sequencing and laboratory services. It features a technology platform that serves as a transformative library prep technology that allows for simple, scalable multiplexing of 100s to 1000s of samples without time- and cost-consuming normalization. The company was founded in 2014 and headquartered in Massachusetts, United States.
Pheon Therapeutics is an Antibody-Drug Conjugate (ADC) specialist that creates ADCs for a variety of difficult-to-treat cancers. Its lead program is a first-in-class ADC against a novel target that is highly expressed in solid tumors across a broad range of hard-to-treat cancer types. The company was founded in 2022 and is based in London, England.
Q'Apel Medical, founded in 2016 and headquartered in Fremont, California, specializes in developing access device technology for neurovascular interventions. The company's medical devices are designed to assist physicians in overcoming challenges related to the delivery of neurovascular procedures, particularly in the treatment of stroke and cerebral aneurysms. By enhancing trackability in navigating complex neurovascular pathways, Q'Apel Medical aims to improve both clinical effectiveness and patient outcomes in these critical medical interventions.
Translational Drug Development, LLC is a biotechnology company specializing in preclinical services for oncology medicine development. Founded in 2003 and located in Scottsdale, Arizona, the company offers a range of services including regulatory strategic guidance, planning and document submission, as well as clinical trial design and execution tailored for oncology-focused organizations. Their platform is designed to support clinical programs that identify specific contexts of sensitivity for novel therapies, facilitating more effective patient benefits during clinical testing. This approach empowers oncology researchers to properly assess and prepare cancer drugs, ultimately advancing the field of cancer treatment.
Halo Labs is a life science instrumentation company based in Burlingame, California, that specializes in developing tools for biologics researchers. Formerly known as Optofluidics, the company focuses on high throughput biopharmaceutical quality control, utilizing advanced optics, image processing, and microfluidics technology. Its offerings include tools for biologics-developability assessment, formulation development, small molecule solubility, and AAV analytics. Founded in 2011, Halo Labs has gained recognition in the industry, receiving support from notable investors and partners such as BioAdvance and the National Science Foundation. The company aims to provide researchers with accurate insights into the stability and quality of biological drugs.
SeqWell’s is a biotechnology company that specializes in the fields of gene sequencing and laboratory services. It features a technology platform that serves as a transformative library prep technology that allows for simple, scalable multiplexing of 100s to 1000s of samples without time- and cost-consuming normalization. The company was founded in 2014 and headquartered in Massachusetts, United States.
Halo Labs is a life science instrumentation company based in Burlingame, California, that specializes in developing tools for biologics researchers. Formerly known as Optofluidics, the company focuses on high throughput biopharmaceutical quality control, utilizing advanced optics, image processing, and microfluidics technology. Its offerings include tools for biologics-developability assessment, formulation development, small molecule solubility, and AAV analytics. Founded in 2011, Halo Labs has gained recognition in the industry, receiving support from notable investors and partners such as BioAdvance and the National Science Foundation. The company aims to provide researchers with accurate insights into the stability and quality of biological drugs.
BioInformatics, LLC is a market research and advisory firm that serves the life science, medical device, pharmaceutical, and diagnostic industries. The company specializes in both primary and secondary research, providing insights on market size, attractiveness, and product optimization. Key services include product concept testing, pricing strategy analysis, customer satisfaction assessments, and brand strength evaluations. BioInformatics helps clients navigate corporate acquisitions and measure brand loyalty, offering tailored research that informs strategic decisions. With a multidisciplinary team of industry veterans and research experts, the firm supports clients in enhancing their market positioning and developing effective marketing strategies. Founded in 1994 and based in Arlington, Virginia, BioInformatics caters to a diverse clientele, including biotechnology firms, medical diagnostics companies, and professional service providers.
AustinPx operates as a contract development and manufacturing organization that specializes in analytical and formulation development services, as well as cGMP manufacturing for small molecule drugs. The company provides comprehensive preclinical services through Phase II formulation and process development, along with GMP manufacturing of oral dosage forms. This enables healthcare providers to concentrate on creating innovative therapeutics from poorly bioavailable drugs, ultimately delivering enhanced clinical benefits to patients.
OrthAlign is a privately-held medical device company providing healthier and more pain-free lifestyles to joint replacement patients. The company is developing a line of computer-assisted surgical devices that distill the critical features and benefits of large surgical navigation systems. Its goal is to create a new standard of care in total joint replacement, making consistent, and measurable results accessible to surgeons and patients. The company was founded in 2009 and based in Aliso Viejo, California.
Rubicon Genomics, Inc. is a biotechnology company based in Ann Arbor, Michigan, focused on developing nucleic acid library preparation and amplification technologies. Founded in 2000 by two faculty members from the University of Michigan, the company aims to translate human genetics research into practical medical applications. Rubicon offers a range of products, including the ThruPLEX and PicoPLEX series, which provide high sensitivity ligation-based and quasi-random primed amplification solutions for analyzing clinical research samples. These products are designed to improve the detection of DNA methylation patterns in cancer cells and facilitate non-invasive diagnostic tests by amplifying small amounts of abnormally methylated DNA found in bodily fluids. Rubicon sells its products through distributors and its online platforms, maintaining a commitment to supporting the Michigan economy while establishing itself as a leader in pre-analytical amplification technologies.
CyMedica Orthopedics, Inc. is a medical device company focused on developing and commercializing innovative products for joint injuries and the associated muscle atrophy. Founded in 2013 and based in Scottsdale, Arizona, CyMedica offers a range of orthopedic solutions that utilize proprietary neuromuscular electrical stimulation technology. Its flagship product, e-vive, provides individualized muscle stimulation therapy through a wireless and app-controlled system, allowing patients to engage in their rehabilitation while tracking progress and sharing data with clinicians. Additionally, the company offers a variety of products, including the Conductive garment, which ensures effective muscle activation, the ACL Brace for post-operative support, and The QB1 System, designed to empower patients in overcoming quadricep weakness. These devices aim to stabilize joints, prevent muscle weakening during recovery, and improve patient outcomes while reducing the likelihood of readmission.
AustinPx operates as a contract development and manufacturing organization that specializes in analytical and formulation development services, as well as cGMP manufacturing for small molecule drugs. The company provides comprehensive preclinical services through Phase II formulation and process development, along with GMP manufacturing of oral dosage forms. This enables healthcare providers to concentrate on creating innovative therapeutics from poorly bioavailable drugs, ultimately delivering enhanced clinical benefits to patients.
Providence Medical Technology is a medical device company dedicated to developing innovative solutions for cervical spine conditions in the United States and internationally. The company specializes in the design of surgical instrumentation and implants that address cervical degenerative disc disease through a unique approach to indirect decompression and fusion. Its primary offerings include the DTRAX Spinal System, which consists of single-use disposable instruments for accessing the spine via posterior incisions, and the DTRAX Cervical Cage, designed to treat cervical radiculopathy by facilitating indirect decompression and fusion. Additionally, the company provides the DTRAX Graft, a structural allograft for posterior fusion support, and the DTRAX Facet System, a sterile kit containing necessary tools and implants for single-level surgeries. Providence Medical Technology distributes its products through a network of distributors and sales representatives and is headquartered in Lafayette, California.
ClearFlow, Inc. is a medical device company specializing in the development and manufacturing of active blood and fluid evacuation systems to address catheter obstructions. The company's primary product, the PleuraFlow Active Clearance Technology system, is designed to clear chest tubes, preventing the retention of blood and fluids in the chest cavity, particularly for pediatric cardiothoracic surgery patients. This innovative technology allows for improved postoperative blood evacuation, enabling the use of minimally invasive drainage tubes, which can enhance patient comfort and reduce surgical complications. ClearFlow is expanding its product pipeline based on its proprietary technologies to tackle catheter clogging across various medical segments, including urinary and gastrointestinal catheters, as well as wound drainage. Founded in 2006 and based in Anaheim, California, the company also operates a service center in Maastricht, the Netherlands.
OrthAlign is a privately-held medical device company providing healthier and more pain-free lifestyles to joint replacement patients. The company is developing a line of computer-assisted surgical devices that distill the critical features and benefits of large surgical navigation systems. Its goal is to create a new standard of care in total joint replacement, making consistent, and measurable results accessible to surgeons and patients. The company was founded in 2009 and based in Aliso Viejo, California.
OrthAlign is a privately-held medical device company providing healthier and more pain-free lifestyles to joint replacement patients. The company is developing a line of computer-assisted surgical devices that distill the critical features and benefits of large surgical navigation systems. Its goal is to create a new standard of care in total joint replacement, making consistent, and measurable results accessible to surgeons and patients. The company was founded in 2009 and based in Aliso Viejo, California.
Esperance Pharmaceuticals Inc. is a biotechnology company based in Houston, Texas, focused on developing targeted anticancer drugs for women with ovarian and breast cancer. The company's key product, EP-100, is an oncolytic peptide designed to selectively bind to receptors for luteinizing hormone releasing hormone (LHRH) found on cancer cells, enabling it to destroy these cells while sparing normal tissue. This innovative approach allows the drug to effectively target both dividing and non-dividing cancer cells, including those resistant to traditional chemotherapy. Esperance has formed a strategic alliance with MD Anderson Cancer Center to expedite the clinical development of EP-100, further enhancing its commitment to advancing cancer treatment. The company was incorporated in 2005 and is dedicated to improving outcomes for patients through its novel therapeutic strategies.
Cylene Pharmaceuticals, Inc., a biotech pharmaceutical company, engages in the discovery, development, and commercialization of small molecule drugs that target nucleolus and kill cancer cells. It offers nucleolus targeting agents, which are small-molecule targeted cancer therapeutic agents for carcinoid/neuroendocrine tumors and pediatric brain tumors; and serine/threonine protein kinase inhibitors. The company also provides pre-clinical stage oral drug candidates. Cylene Pharmaceuticals, Inc. was founded in 1997 as Cyternex, Inc. and changed its name to Cylene Pharmaceuticals, Inc. in October 2003. The company is based in San Diego, California.
Esperance Pharmaceuticals Inc. is a biotechnology company based in Houston, Texas, focused on developing targeted anticancer drugs for women with ovarian and breast cancer. The company's key product, EP-100, is an oncolytic peptide designed to selectively bind to receptors for luteinizing hormone releasing hormone (LHRH) found on cancer cells, enabling it to destroy these cells while sparing normal tissue. This innovative approach allows the drug to effectively target both dividing and non-dividing cancer cells, including those resistant to traditional chemotherapy. Esperance has formed a strategic alliance with MD Anderson Cancer Center to expedite the clinical development of EP-100, further enhancing its commitment to advancing cancer treatment. The company was incorporated in 2005 and is dedicated to improving outcomes for patients through its novel therapeutic strategies.
Cantex Pharmaceuticals is a biotechnology company focused on developing innovative cancer treatments by modifying existing therapies. The company has two primary development programs that utilize known chemical entities to address significant unmet medical needs in oncology. One of its key products is ODSH, a low anticoagulant heparin derivative aimed at mitigating the adverse effects of chemotherapy on platelet counts. Additionally, Cantex offers Disulfiram-Copper Chelate, which employs multiple mechanisms to target cancer stem cells, making it a potential treatment option for metastatic breast cancer, pancreatic cancer, and glioblastoma. Established in 2002 and based in Weston, Florida, Cantex Pharmaceuticals is dedicated to creating safer and more effective therapeutic options for patients facing life-threatening disorders.
Cryofluor Therapeutics
Venture Round in 2005
CryoFluor Therapeutics engages in the development of medical devices to treat various diseases using a liquid cryogenic technology.
Cantex Pharmaceuticals is a biotechnology company focused on developing innovative cancer treatments by modifying existing therapies. The company has two primary development programs that utilize known chemical entities to address significant unmet medical needs in oncology. One of its key products is ODSH, a low anticoagulant heparin derivative aimed at mitigating the adverse effects of chemotherapy on platelet counts. Additionally, Cantex offers Disulfiram-Copper Chelate, which employs multiple mechanisms to target cancer stem cells, making it a potential treatment option for metastatic breast cancer, pancreatic cancer, and glioblastoma. Established in 2002 and based in Weston, Florida, Cantex Pharmaceuticals is dedicated to creating safer and more effective therapeutic options for patients facing life-threatening disorders.
NP Photonics, Inc. develops and manufactures specialty fiber lasers, fiber amplifiers, and transport fibers for the near- and mid-infrared wavelength bands. The company offers a range of products, including micron fiber lasers, multi-channel fiber laser systems, and light sources, which are utilized in various applications such as acoustic sensing, LIDAR, coherent communication, and metrology. NP Photonics serves markets in sensing, defense, and research through distributors and sales representatives across multiple countries, including Australia, Germany, Japan, and the United Kingdom. Founded in 1998 and based in Tucson, Arizona, the company was formerly known as NP Photonic Technologies, LLC, before changing its name in August 2000.